




RealRate

PHARMACEUTICAL 2020

BeiGene Ltd.
Rank 196 of 358





RealRate

PHARMACEUTICAL 2020

BeiGene Ltd.
Rank 196 of 358



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 26% points. The greatest weakness of BeiGene Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 65%, being 29% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	1,172,696
Cost of Goods Sold	71,190
Intangible Assets	5,846
Liabilities, Current	310,312
Liabilities, Non-Current	323,622
Other Assets	191,345
Other Compr. Net Income	-7,577
Other Expenses	8,318
Other Liabilities	0
Other Net Income	16,305
Other Revenues	428,212
Property and Equipment	242,402
Research and Development	927,338
Selling, General and Administrative Expense	388,249

Output Variable	Value in 1000 USD
Assets	1,612,289
Liabilities	633,934
Expenses	1,395,095
Revenues	428,212
Stockholders Equity	978,355
Net Income	-950,578
Comprehensive Net Income	-954,366
Economic Capital Ratio	65%